SynthesisBMC neurology2026
Association between iron deposition and emotional disorder in Parkinson's patients: a systematic review and meta-analysis.
Synthesis in BMC neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Iron dyshomeostasis and its neurobiological mechanisms in psychiatric disorders.Molecular psychiatry · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
objectiveDepression, anxiety and apathy are the most common emotional symptoms in patients with Parkinson’s disease (PD). However, the association between these symptoms and brain iron deposition remains unclear. This study aimed to systematically evaluate the strength of association between brain iron deposition and anxiety, depression, and apathy in PD patients.
methodsA systematic search was conducted in PubMed, Embase, and Web of Science databases from their inception to September 2025 to include eligible observational studies investigating the association between brain iron deposition and anxiety, depression, or apathy in PD patients. Heterogeneity among studies was assessed via Cochran’s Q test and I2 statistic, and a fixed-effects or random-effects model was selected to pool effect sizes based on the heterogeneity level. Subgroup analyses (stratified by outcome measures and brain regions), sensitivity analysis, and publication bias assessment (Egger’s test and Begg’s test) were conducted to verify the robustness of the results.
resultsA total of 8 cross-sectional studies were finally included, with a total sample size of 855. The overall risk of bias of the included studies was manageable. Meta-analysis results showed a significant association between brain iron deposition and the occurrence of anxiety and depression in PD patients, with a pooled standardized mean difference (SMD) of 0.95 (95% confidence interval [95%CI]: 0.73–1.17). The results of the subgroup analysis showed that the results of the depression subgroup were highly stable (I2 = 25%). In brain region stratification, iron deposition in the substantia nigra (SMD = 1.01, 95%CI: 0.82–1.19) and general subcortical nuclei (SMD = 0.53, 95%CI: 0.23–0.84) were significantly associated with emotional symptoms, and the heterogeneity among the subgroups was low. Only 1 study was included in the apathy subgroup or the cortical subgroup.
conclusionBrain iron deposition in PD patients is significantly associated with the occurrence of anxiety and depression, with the substantia nigra and general subcortical nuclei as the core associated brain regions. These findings can provide potential biomarkers for the early prediction and targeted intervention of emotional symptoms in PD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.